A new synthesis of the GPIIb/IIIa receptor antagonist SB-214857-A

被引：23

作者：

Andrews, IP ^{[1
]}

Atkins, RJ ^{[1
]}

Badham, NF ^{[1
]}

Bellingham, RK ^{[1
]}

Breen, GF ^{[1
]}

Carey, JS ^{[1
]}

Etridge, SK ^{[1
]}

Hayes, JF ^{[1
]}

Hussain, N ^{[1
]}

Morgan, DO ^{[1
]}

Share, AC ^{[1
]}

Smith, SAC ^{[1
]}

Walsgrove, TC ^{[1
]}

Wells, AS ^{[1
]}

机构：

[1] GlaxoSmithKline Pharmaceut, Synthet Chem, Tonbridge TN11 9AN, Kent, England

来源：

TETRAHEDRON LETTERS | 2001年 / 42卷 / 29期

关键词：

asymmetric synthesis; benzodiazepine; carbonylation; enzyme reaction; epimerisation; hydrogenation;

D O I：

10.1016/S0040-4039(01)00843-7

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

A new synthesis of lotrafiban SB-214857-A is reported. The key steps are the preparation of racemic (4-melhyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[c][1,4]diazepin-2-yl)-acid methyl ester from 2-nitrobenzyl alcohol, a resolution using an immobilised lipase enzyme and a palladium-catalysed aminocarbonylation reaction. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：4915 / 4917

页数：3

共 50 条

[41] Identification and characterization of antibodies that bind GPIIb/IIIa: Antagonist complexes
Breth, L
Kochie, J
Combs, A
Wang, S
Smallheer, J
Billheimer, J
Selffert, D
Hollis, G
O'Neil, K
JOURNAL OF IMMUNOLOGICAL METHODS, 2005, 301 (1-2) : 11 - 20
[42] UR-3216: A manageable oral GPIIb/IIIa antagonist
Baba, K
Aga, Y
Nakanishi, T
Motoyama, T
Ueno, H
CARDIOVASCULAR DRUG REVIEWS, 2001, 19 (01): : 25 - 40
[43] GPIIb/IIIa antagonist isoxazolinylacetamides having a modified amide linkage
Wityak, J
Batt, DG
Tobin, AE
Mousa, SA
Racanelli, AL
Hausner, EA
Olson, RE
Wexler, RR
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 96 - MEDI
[44] Quantitative detection of platelet GPIIb-IIIa receptor antagonist activity using a flow cytometric method
Green, LJ
Marder, P
Um, SL
Jakubowski, JA
Lawrence, JB
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1998, 12 (04) : 191 - 196
[45] Intranasal antiplatelet/antithrombotic efficacy of a novel platelet GPIIB/IIIA receptor antagonist DMP755
Mousa, SA
Mu, DX
Hussain, MA
THROMBOSIS RESEARCH, 1998, 92 (03) : 115 - 124
[46] Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802
Mousa, SA
Olson, RE
Bozarth, JM
Lorelli, W
Forsythe, MS
Racanelli, A
Gibbs, S
Schlingman, K
Bozarth, T
Kapil, R
Wityak, J
Sielecki, TM
Wexler, RR
Thoolen, MJ
Slee, A
Reilly, TM
Anderson, PS
Friedman, PA
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (02) : 169 - 176
[47] Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs
Rebello, SS
Kasiewski, CJ
Bentley, RG
Morgan, SR
Chu, V
Bostwick, JS
Klein, SI
Perrone, MH
Leadley, RJ
THROMBOSIS RESEARCH, 2001, 102 (03) : 261 - 271
[48] Discovery of a novel non peptide antiplatelet GPIIb/IIIa receptor antagonist, DMP 754: Receptor binding affinity and specificity
Mousa, SA
Bozarth, J
Forsythe, M
Xue, CB
Wityak, J
Olson, R
Thoolen, MJ
Reilly, TM
CIRCULATION, 1996, 94 (08) : 3006 - 3006
[49] Antiplatelet efficacy of orally administered DMP802, a GPIIb/IIIa receptor antagonist, in the conscious dog
Reilly, TM
Racanelli, AL
Olson, RE
Wityak, J
Wexler, RR
Hausner, EA
Thoolen, MJ
Mousa, SA
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (02) : 7122 - 7122
[50] TETRAFIBRICIN HAS A HIGH SELECTIVITY FOR GPIIB/IIIA - COMPARISON OF THE EFFECTS OF TETRAFIBRICIN AND RGDS ON GPIIB/IIIA AND THE VITRONECTIN RECEPTOR
SATOH, T
KOUNS, WC
YAMASHITA, Y
KAMIYAMA, T
STEINER, B
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 204 (01) : 325 - 332

← 1 2 3 4 5 →